Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $322.0K | $329.0K | $372.0K | $445.0K |
| Gross profit | $0 | $0 | $0 | $0 | −$322.0K | −$329.0K | −$372.0K | −$445.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $10.1M | $12.6M | $11.1M | $4.9M | $5.6M | $3.9M | $4.4M | $5.2M |
| Operating income | −$22.4M | −$24.1M | −$24.6M | −$12.8M | −$11.5M | −$9.1M | −$9.9M | −$10.7M |
| EBITDA | −$32.5M | −$22.7M | −$26.3M | −$23.1M | −$10.6M | −$8.8M | −$9.5M | −$9.9M |
| Net income | −$33.3M | −$23.4M | −$26.7M | −$46.2M | −$12.2M | −$9.1M | −$9.9M | −$10.2M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -23610.21 | -14170.50 | -15221.97 | -3725.15 | -912.63 | -32.80 | -7.47 | -6.62 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds NVIV.
No tracked institution reports a position in NVIV as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-04-27 | 1-for-25reverse |
| 2020-02-12 | 1-for-30reverse |
| 2018-04-17 | 1-for-25reverse |
| 2015-04-08 | 1-for-4reverse |
No one on the platform has traded NVIV yet.
| +100.00% |
| $1M |
| — |
| HTGMQHTG Molecular Diagnostics, Inc. | $0.00 | +0.00% | $221 | — |
| IMPLImpel Pharmaceuticals Inc. | $0.04 | -27.27% | $956000 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.